Prognostic factors and clinical hallmarks of low grade serous ovarian carcinoma: a single center study

Abstract

Ovarian cancer is the most fatal gynecologic malignancy. Low-grade type represents only 2-5% of all ovarian cancer pathological types. Its clinical characteristics, growth pattern, and response to treatment are distinct from high-grade serous ovarian carcinoma. In this study, we retrospectively evaluated the clinical features, prognostic factors, and survival of patients diagnosed with low-grade serous ovarian cancer from a tertiary cancer centre. This is a retrospective study where all patients diagnosed with lowgrade serous ovarian cancer (LGSOC) who presented to a tertiary cancer centre from July 2015 to August 2021 were included. Forty-two patients with low-grade ovarian serous carcinoma were enrolled. The mean age of the patients was 50.17 ± 10.91 years, while the mean Body Mass Index (BMI) was 32.96 ± 6.02 kg/m 2 . Primary optimal debulking was performed in 18 patients, while interval cytoreduction was done in 17 patients. Suboptimal debulking was performed in 5 patients. Neoadjuvant chemotherapy was administered in 19 patients (45.2%). The median overall survival of LGSOC patients was 95.58 (73.37-117.79) months while the median Progression free survival (PFS) was 56.54 (38.15-74.94) months. Primary cytoreductive surgery is still the cornerstone of the management of LGSOC patients. Neoadjuvant chemotherapy could be a predictor of worse progression-free survival in LGSOC patients presented with advanced disease stage.